Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Acute leukemia

Long-term follow-up of a retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic transplantation from matched related donors in myelodysplastic syndromes

Bone Marrow Transplantation volume 52, pages 1107–1112 (2017)Cite this article

Subjects

Abstract

This study shows the long-term updated outcomes of a multicenter retrospective study which analyzed 843 patients with myelodysplastic syndrome (MDS) who underwent transplantation with an HLA-identical sibling donor with either reduced-intensity conditioning (RIC) in 213 patients, or standard myeloablative conditioning (MAC) in 630 patients. In multivariate analysis, the 13-year relapse rate was significantly increased after RIC (31% after MAC vs 48% in RIC; HR, 1.5; 95% CI, 1.1–1.9; P=0.04), but with no differences in overall survival (OS) (30% after MAC vs 27% in RIC; P=0.4) and PFS (29 vs 21%, respectively, P=0.3). Non-relapse mortality was higher in MAC (40 vs 31%; P=0.1), especially in patients older than 50 years (50 vs 33%, P<0.01). In addition, long-term follow-up confirms the importance of other variables on 13-year OS, mainly MDS risk category, disease phase, cytogenetics and receiving a high donor cell dose, irrespective of the conditioning regimen used.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Onida F, Brand R, van BA, Schaap M, von dem Borne PA, Maertens J et al. Impact of the International Prognostic Scoring System cytogenetic risk groups on the outcome of patients with primary myelodysplastic syndromes undergoing allogeneic stem cell transplantation from human leukocyte antigen-identical siblings: a retrospective analysis of the European Society for Blood and Marrow Transplantation-Chronic Malignancies Working Party. Haematologica 2014; 99: 1582–1590.

    Article  Google Scholar 

  2. Kroger N, Zabelina T, de Wreede L, Berger J, Alchalby H, van Biezen A et al. Allogeneic stem cell transplantation for older advanced MDS patients: improved survival with young unrelated donor in comparison with HLA-identical siblings. Leukemia 2013; 27: 604–609.

    Article  CAS  Google Scholar 

  3. Brand R, Putter H, van BA, Niederwieser D, Martino R, Mufti G et al. Comparison of allogeneic stem cell transplantation and non-transplant approaches in elderly patients with advanced myelodysplastic syndrome: optimal statistical approaches and a critical appraisal of clinical results using non-randomized data. PLoS ONE 2013; 8: e74368.

    Article  CAS  Google Scholar 

  4. Malcovati L, Hellstrom-Lindberg E, Bowen D, Ades L, Cermak J, Del CC et al. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood 2013; 122: 2943–2964.

    Article  CAS  Google Scholar 

  5. Deschler B, de Witte T, Mertelsmann R, Lubbert M . Treatment decision-making for older patients with high-risk myelodysplastic syndrome or acute myeloid leukemia: problems and approaches. Haematologica 2006; 91: 1513–1522.

    PubMed  Google Scholar 

  6. Alessandrino EP, Porta MG, Malcovati L, Jackson CH, Pascutto C, Bacigalupo A et al. Optimal timing of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome. Am J Hematol 2013; 88: 581–588.

    Article  Google Scholar 

  7. Martino R, de Wreede L, Fiocco M, van Biezen A, von dem Borne PA, Hamladji RM et al. Comparison of conditioning regimens of various intensities for allogeneic hematopoietic SCT using HLA-identical sibling donors in AML and MDS with &lt;10% BM blasts: a report from EBMT. Bone Marrow Transplant 2013; 48: 761–770.

    Article  CAS  Google Scholar 

  8. Martino R, Iacobelli S, Brand R, Jansen T, van BA, Finke J et al. Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes. Blood 2006; 108: 836–846.

    Article  CAS  Google Scholar 

  9. Finke J, Schmoor C, Bertz H, Marks R, Wasch R, Zeiser R et al. Long-term follow-up of therapy-related myelodysplasia and AML patients treated with allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2016; 51: 771–777.

    Article  CAS  Google Scholar 

  10. Potter VT, Krishnamurthy P, Barber LD, Lim Z, Kenyon M, Ireland RM et al. Long-term outcomes of alemtuzumab-based reduced-intensity conditioned hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myelogenous leukemia secondary to myelodysplastic syndrome. Biol Blood Marrow Transplant 2014; 20: 111–117.

    Article  CAS  Google Scholar 

  11. Boehm A, Sperr WR, Kalhs P, Greinix H, Valent P, Worel N et al. Long-term follow-up after allogeneic stem cell transplantation in patients with myelodysplastic syndromes or secondary acute myeloid leukemia: a single center experience. Wien Klin Wochenschr 2014; 126: 23–29.

    Article  CAS  Google Scholar 

  12. Wingard JR, Majhail NS, Brazauskas R, Wang Z, Sobocinski KA, Jacobsohn D et al. Long-term survival and late deaths after allogeneic hematopoietic cell transplantation. J Clin Oncol 2011; 29: 2230–2239.

    Article  Google Scholar 

  13. Atallah E, Abrams J, Ayash L, Bentley G, Abidi M, Ratanatharathorn V et al. Long term follow-up of allogeneic stem cell transplantation in patients with myelodysplastic syndromes using busulfan, cytosine arabinoside, and cyclophosphamide. Am J Hematol 2010; 85: 579–583.

    Article  CAS  Google Scholar 

  14. Shimoni A, Hardan I, Shem-Tov N, Yerushalmi R, Nagler A . Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: long-term follow-up. Leukemia 2010; 24: 1050–1052.

    Article  CAS  Google Scholar 

  15. la Porta MG, Alessandrino EP, Bacigalupo A, van Lint MT, Malcovati L, Pascutto C et al. Predictive factors for the outcome of allogeneic transplantation in patients with MDS stratified according to the revised IPSS-R. Blood 2014; 123: 2333–2342.

    Article  Google Scholar 

  16. Neukirchen J, Lauseker M, Blum S, Giagounidis A, Lubbert M, Martino S et al. Validation of the revised international prognostic scoring system (IPSS-R) in patients with myelodysplastic syndrome: a multicenter study. Leuk Res 2014; 38: 57–64.

    Article  Google Scholar 

  17. Lee JH, Lee JH, Lim SN, Kim DY, Kim SH, Lee YS et al. Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome: prognostic significance of pre-transplant IPSS score and comorbidity. Bone Marrow Transplant 2010; 45: 450–457.

    Article  Google Scholar 

  18. Nevill TJ, Shepherd JD, Sutherland HJ, bou Mourad YR, Lavoie JC, Barnett MJ et al. IPSS poor-risk karyotype as a predictor of outcome for patients with myelodysplastic syndrome following myeloablative stem cell transplantation. Biol Blood Marrow Transplant 2009; 15: 205–213.

    Article  Google Scholar 

  19. Mukherjee S, Boccaccio D, Sekeres MA, Copelan E . Allogeneic hematopoietic cell transplantation for myelodysplastic syndromes: lingering uncertainties and emerging possibilities. Biol Blood Marrow Transplant 2015; 21: 412–420.

    Article  Google Scholar 

  20. Raimondi R, Tosetto A, Oneto R, Cavazzina R, Rodeghiero F, Bacigalupo A et al. Validation of the hematopoietic cell transplantation-specific comorbidity index: a prospective, multicenter GITMO study. Blood 2012; 120: 1327–1333.

    Article  CAS  Google Scholar 

  21. Kroger N . Allogeneic stem cell transplantation for elderly patients with myelodysplastic syndrome. Blood 2012; 119: 5632–5639.

    Article  Google Scholar 

  22. Parmar S, de Lima M, Deeg HJ, Champlin R . Hematopoietic stem cell transplantation for myelodysplastic syndrome: a review. Semin Oncol 2011; 38: 693–704.

    Article  Google Scholar 

  23. Warlick ED . Optimizing stem cell transplantation in myelodysplastic syndromes: unresolved questions. Curr Opin Oncol 2010; 22: 150–154.

    Article  Google Scholar 

  24. Scott BL, Pasquini MC, Logan B, Wu J, Devine S, Porter DL et al. Results of a phase III randomized, multi-center study of allogeneic stem cell transplantation after high versus reduced intensity conditioning in patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML): Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0901. Blood 2015; 126 (23). Late Breaking Abstracts 8.

Download references

Acknowledgements

Author contributions

RM designed the study, performed data analysis and wrote the various versions of the manuscript. AH was the main data manager. MR, TdW and NK designed the study, coordinated all the steps from design to the final data analysis, and participated in the development of all versions of the manuscript. All other coauthors participated in data management and in the development of all versions of the manuscript.

Author information

Authors and Affiliations

  1. Hospital Santa Creu i Sant Pau, Barcelona, Spain

    R Martino & J Sierra

  2. EBMT Data Office, Leiden, The Netherlands

    A Henseler

  3. Ospedale San Martino, Genova, Italy

    M van Lint

  4. Radboud University-Nijmegen Medical Center, Nijmegen, The Netherlands

    N Schaap & T de Witte

  5. University of Freiburg, Freiburg, Germany

    J Finke

  6. University Hospital, Essen, Germany

    D Beelen

  7. Hôpital Haut-Leveque, Pessac, France

    S Vigouroux

  8. Fondazione IRCCS Policlinico San Matteo, Pavia, Italy

    E P Alessandrino

  9. GKT School of Medicine, London, UK

    G J Mufti

  10. Leiden University Hospital, Leiden, The Netherlands

    J H Veelken

  11. A.O.U Citta della Salute e della Scienza di Torino, Torino, Italy

    B Bruno

  12. CHU de Lille, CIRIC INSERM U995, Université de Lille 2, Lille, France

    I Yakoub-Agha

  13. HUCH Comprehensive Cancer Center, Helsinki, Finland

    L Volin

  14. University Hospital Gasthuisberg, Leuven, Belgium

    J Maertens

  15. Hadassah University Hospital, Jerusalem, Israel

    R Or

  16. Universite Paris IV, Hopital la Pitié-Salpêtrière, Paris, France

    V Leblond

  17. Hospital Clinic, Barcelona, Spain

    M Rovira

  18. Medizinische Universitaet Wien, Vienna, Austria

    P Kalhs

  19. Hospital de la Princesa, Madrid, Spain

    A F Alvarez

  20. Institute of Hematology and Blood Transfusion, Prague, Czech Republic

    A Vitek

  21. University Medical Center Mainz, Mainz, Germany

    E Wagner

  22. Hopital St. Louis, Paris, France

    M Robin

  23. University Hospital Eppendorf, Hamburg, Germany

    N Kröger

Authors
  1. R Martino
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A Henseler
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M van Lint
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. N Schaap
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J Finke
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. D Beelen
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. S Vigouroux
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. E P Alessandrino
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. G J Mufti
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. J H Veelken
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. B Bruno
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. I Yakoub-Agha
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. L Volin
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. J Maertens
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. R Or
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. V Leblond
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. M Rovira
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. P Kalhs
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. A F Alvarez
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. A Vitek
    View author publications

    You can also search for this author in PubMed Google Scholar

  21. J Sierra
    View author publications

    You can also search for this author in PubMed Google Scholar

  22. E Wagner
    View author publications

    You can also search for this author in PubMed Google Scholar

  23. M Robin
    View author publications

    You can also search for this author in PubMed Google Scholar

  24. T de Witte
    View author publications

    You can also search for this author in PubMed Google Scholar

  25. N Kröger
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

for the Myelodysplastic Syndrome subcommittee of the Chronic Malignancies Working Party of the European Blood and Marrow Transplantation Group

Corresponding author

Correspondence to R Martino.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies this paper on Bone Marrow Transplantation website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Martino, R., Henseler, A., van Lint, M. et al. Long-term follow-up of a retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic transplantation from matched related donors in myelodysplastic syndromes. Bone Marrow Transplant 52, 1107–1112 (2017). https://doi.org/10.1038/bmt.2017.19

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2017.19

This article is cited by

Search

Advanced search

Quick links